Ainos (AIMD) Stock

From giving AI the sense of smell and breakthrough in rare disease treatments, Ainos is shaping 2025 with bold technologies and strategic collaborations SAN DIEGO, CA / ACCESSWIRE / December 18, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and VELDONA ® low-dose interferon therapeutics, is pleased to provide a letter to shareholders from its Chairman of the Board, President, and Chief Executive Officer, Mr. Chun-Hsien (Eddy) Tsai.

The following CORRECTS and REPLACES the release that was issued earlier today: Updated partner for VOC detection platform development From giving AI the sense of smell and breakthrough in rare disease treatments, Ainos is shaping 2025 with bold technologies and strategic collaborations SAN DIEGO, CA / ACCESSWIRE / December 18, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and VELDONA ® low-dose interferon therapeutics, is pleased to provide a letter to shareholders from its Chairman of the Board, President, and Chief Executive Officer, Mr. Chun-Hsien (Eddy) Tsai.

SAN DIEGO, CA / ACCESSWIRE / December 13, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced its participation in the Webull Corporate Connect Service (CCS). This initiative aims to further expand the Company's investor outreach and enhance transparency with its growing shareholder base.

San Diego, California--(Newsfile Corp. - December 2, 2024) - Ainos, Inc. (NASDAQ: AIMD) (NASDAQ: AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today proudly announced the signing of a strategically significant Memorandum of Understanding (MOU) with Taiwan Tanabe Seiyaku Co., Ltd., a subsidiary of Mitsubishi Tanabe Pharma Corporation in Japan, brings extensive pharmaceutical development and manufacturing expertise to the partnership.

IRB approval on track as scheduled Next step is obtaining all regulatory approvals, followed by site initiation visit VELDONA significantly increases unstimulated whole salivary flow in prior Phase 3 studies SAN DIEGO, CA / ACCESSWIRE / November 11, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that it has received Institutional Review Board ("IRB") approval from Shuang Ho Hospital, affiliated with Taipei Medical University (IRB Approval No.: TMU-JIRB No.

Strengthens AI Nose Gas Sensing Technology with Additional Exclusively Licensed Patents Secures Exclusive Rights to Breakthrough Nitrogen-Oxygen Separation Technology with Superior Energy Efficiency and Ultra-Low Carbon Emissions, Advancing Sustainable Medical Practices SAN DIEGO, CA / ACCESSWIRE / October 28, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that it has secured exclusive licensing rights for an additional 28 multi-regional patent assets from its strategic shareholder and product co-developer, Taiwan Carbon Nano Technology Corporation ("TCNT"). These patents encompass innovations in AI Nose gas sensing technology and extend Ainos' technological capabilities with a groundbreaking nitrogen-oxygen separation technology targeting medical applications.

Prioritizing VELDONA®'s development for oral warts in HIV+ patients and Sjogren's syndrome Burgeoning pet care market also presents growth opportunities for VELDONA® SAN DIEGO, CA / ACCESSWIRE / October 24, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, shared promising clinical progress of VELDONA® and its growth opportunities alongside upcoming milestones in the Water Tower Research ("WTR") Small-Cap Spotlight podcast, signaling strong potential for both human and animal health markets. WTR has published a report recapping highlights from the podcast.

Ainos pioneers AI-powered digital nose technology with VOC detection breakthroughs for early disease diagnosis, industrial safety, and human-like sensory capabilities in robots VELDONA® low-dose oral interferon technology demonstrates huge potential in in viral, autoimmune, and veterinary treatments SAN DIEGO, CA / ACCESSWIRE / October 7, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that it continues to push the boundaries of global smart healthcare and immunotherapy innovation. With its AI Nose and VELDONA® low-dose oral interferon technologies, Ainos is not only spearheading advancements in medical technology but also demonstrating significant potential for industrial safety and automation applications.

Next step will be receiving approval from Taiwan Food and Drug Administration (TFDA) SAN DIEGO, CA / ACCESSWIRE / September 25, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced it has received Institutional Review Board (IRB) approval from the National Taiwan University Hospital for its clinical trial focused on treating oral warts in HIV-positive patients. This trial will evaluate VELDONA®, Ainos' low-dose oral interferon formulation, which has received orphan drug designation from the U.S. Food and Drug Administration ("FDA"), as a potential treatment for HIV-related oral warts.